31.08.2021 • NewsSolvay

Solvay in Taiwan Hydrogen Peroxide Venture

Solvay and Taiwan’s Shinkong Synthetic Fibers have agreed to create a joint venture for the development, production and marketing of electronic-grade hydrogen peroxide. The companies aim to close the transaction in the second half of 2021, pending regulatory approvals in Taiwan and other countries.

The new company, Shinsol Advanced Chemicals, will be located close to the Southern Taiwan Science Park near Tainan, aiming to serve the country’s booming semiconductor industry when production goes online in the first quarter of 2023. Initial output will be 30,000 t/y, which Solvay said can be increased easily at a later stage in line with market demand.

“The rapid growth in demand in the Taiwan semiconductor industry is an opportunity to bring our world-leading technology for the best quality of electronic-grade hydrogen peroxide, building on the experience of multiple Solvay plants already operating in Asia, Europe and the US,” said Rodrigo Elizondo, president of Solvay Technology Solutions.

Author: Elaine Burridge, Freelance Journalist

Solvay and Taiwan’s Shinkong Synthetic Fibers have agreed to create a joint...
Solvay and Taiwan’s Shinkong Synthetic Fibers have agreed to create a joint venture for the development and production of electronic-grade hydrogen peroxide. The companies aim to close the transaction in H2 2021, with initial production of 30,000 t/y starting in Q1 2023. (c) Solvay

Company

Logo:

Solvay

Rue du Prince Albert 33
1050 Bruxelles
Belgium

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read